Chinese American Cancer Survivors Writing Study
Launched by NEW YORK UNIVERSITY · Jul 8, 2022
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The Chinese American Cancer Survivors Writing Study is a research project designed to see how effective a writing program, called Expressive Helping (EH), can be for Chinese American cancer survivors. This study is currently looking for participants who are 18 years or older, prefer speaking Mandarin Chinese or Cantonese, and can read and write in either Simplified or Traditional Chinese. To be eligible, you should have completed your main cancer treatment within the last five years, or you may still be taking medication for cancer-related issues.
If you choose to participate, you’ll be asked to engage in writing activities that aim to help you express your feelings and experiences related to your cancer journey. This study is important because it explores new ways to support survivors in managing their emotional health after treatment. Please note that individuals who have difficulty writing or are currently attending support groups more than once a week are not eligible to take part in this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over 18 years old.
- • Prefer speaking in Mandarin Chinese or Cantonese, and able to read and write Simplified or Traditional Chinese.
- • Within 5 years after completing primary treatment or have completed primary treatment but still on medication for managing cancer-related symptoms.
- Exclusion Criteria:
- • Difficulties with writing
- • Current active participation in support groups (i.e., attending more than once per week)
About New York University
New York University (NYU) is a prestigious research institution renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure and a diverse team of leading experts, NYU conducts cutting-edge research across various therapeutic areas, focusing on translating scientific discoveries into effective treatments. The university fosters collaboration among multidisciplinary teams and engages with a broad patient population, ensuring that its trials adhere to the highest ethical standards and regulatory requirements. NYU's dedication to excellence in research and education positions it as a key contributor to the advancement of healthcare and clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
New York, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials